Select Page ::

In Recognition of the Challenges Providers Are Facing, NantHealth is Offering Free Access to NaviNet AllPayer for a Limited Time – Yahoo Finance

Posted on May 8, 2020 by Danzig

Providers to benefit from free access to leading payer-provider collaboration platform through May

NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, will offer free access to the NaviNet AllPayer platform through May 31, 2020. There is no obligation when signing up and, for providers already subscribed to NaviNet AllPayer, free access for the month of May will occur automatically. Providers who are not NaviNet AllPayer customers can learn more at NantHealth.com/Free-AllPayer.

NaviNet AllPayer improves communication and increases collaboration across a secure, easy to use system for exchanging vital data in real time. It gives providers a trusted, fast and cost-effective solution to access over 1,000 health plans using a single login. With this access, providers will be able to check eligibility and benefits at over 1,000 health plans nationwide, including Medicare, Medicaid, other government, commercial and Blue Cross Blue Shield plans. Providers will also be able to check claim status for over 550 health plans.

"Providers are experiencing unprecedented pressure to maintain clinical excellence in the wake of this pandemic," said Ron Louks, Chief Operating Officer, NantHealth. "These pressures are being felt in all aspects of society and need a global response of generosity and support from the private sector. We proudly join that response through our NantHealth Cares initiative by offering free access to NaviNet AllPayer this month. NaviNet AllPayer offers a rich, multi-payer experience that lets providers perform benefit and claim-related inquiries while maximizing efficiencies wherever possible. Were looking forward to extending its capabilities to our full community of providers."

About NantHealth, Inc.

NantHealth, a member of the NantWorks ecosystem of companies, provides leading solutions across the continuum of care for physicians, payers, patients and biopharmaceutical organizations. NantHealth enables the use of cutting-edge data and technology toward the goals of empowering clinical decision support and improving patient outcomes. NantHealths comprehensive product portfolio combines the latest technology in payer/provider platforms that exchange information in near-real time (NaviNet and Eviti), and molecular profiling services that combine comprehensive DNA & RNA tumor-normal profiling with pharmacogenomics analysis (GPS Cancer). For more information, please visit nanthealth.com or follow us on Twitter, Facebook and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200508005514/en/

Contacts

NantHealth Jen HodsonJen@nant.com 562-397-3639

Molecular Diagnostic Market 2020, COVID 19 Breakdown Impact, Industry, Global Trends, Size, Applications, Share, Sale, Growth Insight, New Development…

Posted on May 1, 2020 by Danzig

In Global Molecular Diagnostic Market Research Report, the study analysis was given on a worldwide scale, for instance, present and traditional Molecular Diagnostic growth analysis, competitive analysis, and also the growth prospects of the central regions. The report gives an exhaustive investigation of this market provides an analysis of the industry trends in each of the sub-segments, from sales, revenue and consumption. A quantitative and qualitative analysis of the main players in Global and country level is introduced, from the perspective of sales, revenue and price.

Snapshot:Molecular diagnostics is growing rapidly. Molecular diagnostic tests detect specific sequences in DNA or RNA that may or may not be associated with disease, including single nucleotide polymorphism (SNP), deletions, rearrangements, insertions and others. Clinical applications can be found in at least six general areas: infectious diseases; oncology; pharmacogenomics; genetic disease screening; human leukocyte antigen typing; and coagulation. The global Molecular Diagnostic market size is estimated at xxx million USD with a CAGR xx% from 2015-2019 and is expected to reach xxx Million USD in 2020 with a CAGR xx% from 2020 to 2025. The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Molecular Diagnostic by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.

Request a sample of Molecular Diagnostic Market report @https://martresearch.com/contact/request-sample/1/90749

Product Type Coverage(Market Size & Forecast, Major Company of Product Type etc.):

PCR instrumentISH instrumentGene chip matching Equipment

Company Coverage(Company Profile, Sales Revenue, Price, Gross Margin, Main Products etc.):

RocheAbbottGen-ProbeDanaherThermo FisherSiemensQiagenBDBiomerieuxGE

Application Coverage(Market Size & Forecast, Different Demand Market by Region, Main Consumer Profile etc.):

PrenatalInfectious diseaseCancerOthers

Region Coverage(Regional Production, Demand & Forecast by Countries etc.):

North America (U.S., Canada, Mexico)Europe (Germany, U.K., France, Italy, Russia, Spain etc.)Asia-Pacific (China, India, Japan, Southeast Asia etc.)South America (Brazil, Argentina etc.)Middle East & Africa (Saudi Arabia, South Africa etc.)

At the upcoming section, this report discusses industrial policy, economic environment, in addition cost structures of the industry. And this report encompasses the fundamental dynamics of the market which include drivers, opportunities, and challenges faced by the industry. Additionally, this report showed a keen market study of the main consumers, raw material manufacturers and distributors, etc.

Buy The Report @https://martresearch.com/paymentform/1/90749/Single_User

Major Point of TOC:

Table of Content1 Industry Overview2 Industry Environment (PEST Analysis)3 Molecular Diagnostic Market by Type4 Major Companies List5 Market Competition6 Demand by End Market7 Region Operation8 Marketing & Price9 Research Conclusion

About us:Research is and will always be the key to success and growth for any industry. Most organizations invest a major chunk of their resources viz. time, money and manpower in research to achieve new breakthroughs in their businesses. The outcome might not always be as expected thereby arising the need for precise, factual and high-quality data backing your research. This is where MART RESEARCH steps in and caters its expertise in the domain of market research reports to industries across varied sectors.

Mart Research[emailprotected]+1-857-300-1122

Read the original post:
Molecular Diagnostic Market 2020, COVID 19 Breakdown Impact, Industry, Global Trends, Size, Applications, Share, Sale, Growth Insight, New Development...

Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market to Witness Astonishing Growth With Qiagen NV, GE Healthcare, Agilent…

Posted on May 1, 2020 by Danzig

Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market 2020

This report studies the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. Find the complete Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market analysis segmented by companies, region, type and applications in the report.

The major players covered in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Qiagen NV, GE Healthcare, Agilent Technologies, F Hoffman La Roche, Foundation Medicine, Thermo Fisher Scientific Inc., Leica Biosystems Nussloch GmBH, and Pfizer

The final report will add the analysis of the Impact of Covid-19 in this report Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) industry.

Get a Free Sample Copy @ https://www.reportsandmarkets.com/sample-request/global-pharmacogenomics-technology-theranostics-companion-diagnostics-cdx-market-size-status-and-forecast-2019-2025?utm_source=coleofduty&utm_medium=36

Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market continues to evolve and expand in terms of the number of companies, products, and applications that illustrates the growth perspectives. The report also covers the list of Product range and Applications with SWOT analysis, CAGR value, further adding the essential business analytics. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market research analysis identifies the latest trends and primary factors responsible for market growth enabling the Organizations to flourish with much exposure to the markets.

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Research objectives:

To study and analyze the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market size by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2026.

To understand the structure of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market by identifying its various sub segments.

Focuses on the key global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the size of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

The Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market research report completely covers the vital statistics of the capacity, production, value, cost/profit, supply/demand import/export, further divided by company and country, and by application/type for best possible updated data representation in the figures, tables, pie chart, and graphs. These data representations provide predictive data regarding the future estimations for convincing market growth. The detailed and comprehensive knowledge about our publishers makes us out of the box in case of market analysis.

Table of Contents: Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market

Chapter 1: Overview of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market

Chapter 2: Global Market Status and Forecast by Regions

Chapter 3: Global Market Status and Forecast by Types

Chapter 4: Global Market Status and Forecast by Downstream Industry

Chapter 5: Market Driving Factor Analysis

Chapter 6: Market Competition Status by Major Manufacturers

Chapter 7: Major Manufacturers Introduction and Market Data

Chapter 8: Upstream and Downstream Market Analysis

Chapter 9: Cost and Gross Margin Analysis

Chapter 10: Marketing Status Analysis

Chapter 11: Market Report Conclusion

Chapter 12: Research Methodology and Reference

Key questions answered in this report

What will the market size be in 2026 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

Inquire More about This Report https://www.reportsandmarkets.com/enquiry/global-pharmacogenomics-technology-theranostics-companion-diagnostics-cdx-market-size-status-and-forecast-2019-2025?utm_source=coleofduty&utm_medium=36

About Us:

Reports and Markets is not just another company in this domain but is a part of a veteran group called Algoro Research Consultants Pvt. Ltd. It offers premium progressive statistical surveying, market research reports, analysis & forecast data for a wide range of sectors both for the government and private agencies all across the world. The database of the company is updated on a daily basis. Our database contains a variety of industry verticals that include: Food Beverage, Automotive, Chemicals and Energy, IT & Telecom, Consumer, Healthcare, and many more. Each and every report goes through the appropriate research methodology, Checked from the professionals and analysts.

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Read this article:
Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market to Witness Astonishing Growth With Qiagen NV, GE Healthcare, Agilent...

NantHealth Enhances Interoperability of the NaviNet Open Platform With Expanded API Capabilities – Business Wire

Posted on September 23, 2020 by Danzig

CULVER CITY, Calif.--(BUSINESS WIRE)--NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced a series of secure Application Programming Interfaces (APIs) that will offer provider and revenue cycle organizations connectivity to payers via the NaviNet Open Platform. This update enables faster information retrieval and easier payer access through a secure real-time, HIPAA-compliant gateway to payers. The workflows include Eligibility & Benefits, Claim Status Inquiry, Authorizations, and Referrals. NaviNet also offers APIs for payers to access the secure and flexible NaviNet Open Document Exchange platform.

The NaviNet Open Platform APIs provide benefits to stakeholders across the healthcare industry.

NantHealth is delighted to bring this additional functionality to our network of health plans and providers, leading to enhanced interoperability with automation, security, ease of use and scalability, said Chris House, Senior Vice President, Product Engineering at NantHealth. NaviNet has been a leader in payer-provider engagement for 20 years, creating value through innovation and enabling healthcare to successfully operate more efficiently, resulting in better care for patients and members.

About NantHealth, Inc.

NantHealth, a member of the NantWorks ecosystem of companies, provides leading solutions across the continuum of care for physicians, payors, patients and biopharmaceutical organizations. NantHealth enables the use of cutting-edge data and technology toward the goals of empowering clinical decision support and improving patient outcomes. NantHealths comprehensive product portfolio combines the latest technology in payor/provider platforms that exchange information in near-real time (NaviNet and Eviti), and molecular profiling services that combine comprehensive DNA & RNA tumor-normal profiling with pharmacogenomics analysis (GPS Cancer). For more information, please visit http://www.nanthealth.com or follow us on Twitter, Facebook and LinkedIn.

Read the original post:
NantHealth Enhances Interoperability of the NaviNet Open Platform With Expanded API Capabilities - Business Wire

Denovo Biopharma To Acquire Tocagen’s Entire Replicating Gene Therapy Platform and Related Assets – Yahoo Finance

Posted on April 30, 2020 by Danzig

SAN DIEGO, April 28, 2020 /PRNewswire/ --Denovo Biopharma LLC, a pioneer in applying precision medicine to develop innovative therapies, today announced it is acquiring Tocagen's retroviral replicating vector platform (RRV) in its entirety, including its investigational gene therapy and drug regimen for oncology: Toca 511 and Toca FC (now known as DB107), and several early-stage development programs, including programs targeting PD-L1 and other immunooncology targets. This acquisition is pending the close of Tocagen's anticipated merger with Forte Biosciences. These programs greatly expand Denovo's product portfolio into gene therapy and immunooncology, yet remain consistent with Denovo's precision medicine approach.

Denovo Biopharma provides novel, proprietary biomarker approaches to personalized drug development, including re-evaluating drugs that failed in general patient populations. The company has the first platform for de novo genomic biomarker discovery using archived clinical samples. By retrospectively identifying biomarkers correlated with responses to drugs, Denovo enables clinical trials in targeted patient populations while optimizing efficacy, safety and tolerability. http://www.denovobiopharma.com . (PRNewsFoto/Denovo Biomarkers)

Thelead acquired asset, DB107, is an innovative approach utilizing a proprietary gene therapy platform, RRV, combined with a prodrug, to selectively infect and kill cancer cells while stimulating a robust and durable anti-cancer immune response against a tumor with minimal toxicity. DB107 has been tested clinically in solid tumors including recurrent high grade glioma and colorectal cancer, most recently in a randomized 403-patient Phase 3 trial. Although the Phase 3 trial results were negative overall, there were subsets of patients who showed signs of beneficial activity of DB107. After the acquisition, Denovo will use its unique biomarker platform to search for pharmacogenomic predictor for DB107 efficacy.

"With this strategic acquisition, Denovo gains a pioneering gene therapy platform with unlimited potential. Together with Denovo's world leading precision medicine capabilities, the RRV platform along with lead product candidate DB107 presents us with an unprecedented opportunity to effectively target a wide range of oncology indications," said Wen Luo, Ph.D., Denovo's Chief Executive Officer. "DB107's Phase 3 trial aimed to treat recurrent high grade glioma, which primarily consists of glioblastoma (GBM). This asset, together with our DB102 asset to be tested in the front-line treatment of GBM, positions Denovo as a leader in the field of neuro-oncology that continues to have a high unmet need."

"We are pleased to have a company with the capabilities of Denovo Biopharma acquiring our gene therapy platform technology to build upon the work that was done by our employees and investigators, as well as the patients in our clinical trials," said Marty J. Duvall, Tocagen's Chief Executive Officer.

About Denovo BiopharmaDenovo Biopharma is a clinical stage biopharmaceutical company that applies novel biomarker approaches to re-evaluate medicines that have failed in broad patient populations. The company seeks to discover genomic biomarkers correlated with patients' responses to drug candidates retrospectively. Denovo then designs and executes efficient clinical trials in targeted patient populations to optimize the probability of a successful trial. Denovo is enrolling patients in the U.S. and China with diffuse large B-cell lymphoma (DLBCL) in a Phase 3 clinical trial and will start a Phase 2B study in Glioblastoma (GBM) for its lead product candidate, DB102, which was in-licensed from Eli Lilly. The company has five additional late stage programs targeting major unmet needs: DB103 for schizophrenia, DB104 for depression, DB105 for Alzheimer's Disease, DB106 for acute myeloid leukemia (AML) and DB107 for recurrent high grade glioma. For additional information please visit http://www.denovobiopharma.com.

Contact:Michael F. Haller, Chief Business OfficerDenovo Biopharma LLCmhaller@denovobiopharma.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/denovo-biopharma-to-acquire-tocagens-entire-replicating-gene-therapy-platform-and-related-assets-301047811.html

SOURCE Denovo Biopharma LLC

See original here:
Denovo Biopharma To Acquire Tocagen's Entire Replicating Gene Therapy Platform and Related Assets - Yahoo Finance

Hawaij Is the Spice Blend That Goes Savory, Sweetand In Your Coffee – Yahoo Lifestyle

Posted on April 30, 2020 by Danzig

First there was the cookbook: Amjaad Al-Hussain, who grew up in a Yemeni family in the D.C. area, started collecting recipesfrom her mothers generation and beyondbefore they were lost. After I got married, I recognized that theres this huge gap generationally, where many of my aunts and my mom had certain Yemeni recipes memorized by heart, she says. I found myself constantly calling her and asking questions. A pharmacogenomics expert and Georgetown University adjunct by day, Al-Hussain spent her scant off-hours compiling the recipes into a book, Sifratna: Recipes from Our Yemeni Kitchen, which she self-published in 2018.

After she launched the book, Al-Hussain headed back to the kitchen to develop a second product: hawaij, or hawayij, a spice blend that's a staple of Yemeni cuisine. Though she'd included a recipe for hawaij in Sifratna, Al-Hussain said, "Not everyone has time to buy whole spices and go through the process in order to have that." She figured she'd make it easynow she sells it, premixed, in jars. (And has since added a third product: a children's book.) Warm, fragrant, and a little peppery, hawaij serves as a kind of "multipurpose" spice mix in Yemeni cooking, Al-Hussain saida flavor profile linked with a place, in the manner of garam masala or ras el hanout.

In fact, hawaij has some ingredients in common with both of those mixtures. The most common ingredients used in all Yemeni hawaij would be cumin, coriander, black pepper, turmeric, cardamom, cinnamon, Al-Hussain says. Some people will use very modest quantities of cloves; some will even use nutmeg. In Al-Hussains kitchen, hawaij finds its way into recipes like a warming lentil stew and a spicy chicken soup, into roasted potatoes and simmered okra. Like other folks in the region, Yemenis enjoy rich, comforting fulstewed fava beansfor breakfast; hawaij spices up Al-Hussains recipe for that, as well.

Adding layers of flavor to coffee? There's a hawaij for that.

But you can add a pinch just about anywhere it makes sense, she says: I use it for my vegetable stews. I use it for chicken marinades, fish, meat. My husband has cooked chicken wings with it.

Story continues

Everybodys is different. When it comes to hawaij, every householdsome auntie or some grandmahas their special mix, Al-Hussain says. My moms mothermy maternal grandmotherher hawaij mix was a lot more simple. She only did coriander, cumin, and black pepper, with a little bit of turmeric just to give it some color. Wiser home cooks will leave salt outthat gives an individual more flexibility in adding their own salt.

And just like you can make a margarita with garam masalaor a spiced-pear dessert with ras el hanouthawaij has uses in the kitchen beyond vegetables and proteins. The blend can also be found on countertops and in kitchen cupboards in Israel, where it was brought by Yemenite Jews immigrating in the mid-20th century, and where its one of the most popular spice mixes, according to New York City chef Einat Admony, writing in her cookbook Shuk: From Market to Table, the Heart of Israeli Home Cooking.

In Shuk, Admony provides not one but two recipes for hawaij. One is soup hawaij, a blend of coriander, cumin, turmeric, black pepper, cardamom, and cloves, similar to the mixture that Al-Hussain makes and sells. Its name indicates at least one use for it; so does the name of Admonys other hawaij recipe, sweet coffee hawaij, a blend of cloves, nutmeg, cinnamon, ginger, and cardamom. You know what to do: Sprinkle some into your morning grounds and brew up an exceptionally aromatic pot of coffee. (Or, if you forgot to do that, stir a few pinches of hawaij right into the hot coffee itself.)

But sweet hawaij has a lot of potential beyond thatin baking, for instance. Its a perfect match for pumpkin pies, Admony writes. I used to work in a bakery that added Chinese five-spice powder to its apple pies: Folks eating the pie wouldnt have been able to identify it as such, probably, but it provided that same warming constellation of spices they were familiar with. Sweet hawaij would likewise be a killer addition to apple pie, or in any baking recipe, really, that would benefit from a little spice. Order it online or blend it yourself, then try the mixture out in gingerbread, fruit crisps, apple pie, oatmeal cookies, pain depices, carrot muffins (or carrot cake!). Or simply put it in your morning oatmeal. Monotony is rampant on this planet at the moment; adding some spice where theres usually none can go a long way.

Originally Appeared on Epicurious

The rest is here:
Hawaij Is the Spice Blend That Goes Savory, Sweetand In Your Coffee - Yahoo Lifestyle

Interpace Biosciences to Host Conference Call and Webcast to Discuss First Quarter, 2020 Financial Results on Thursday June 25, 2020 – GlobeNewswire

Posted on July 1, 2020 by Danzig

PARSIPPANY, NJ, June 24, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences (IDXG) announced today that it will report its first quarter, 2020 financial results on Thursday, June 25, 2020 at 4:30 p.m. ET. Interpace will host a conference call and webcast to discuss the Companys financial results and provide a general business update.

The conference call can be accessed as follows:

Webcast Access: http://public.viavid.com/index.php?id=140471

Following the conclusion of the conference call, a replay will be available through July 9, 2020. The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Companys website at http://www.interpacediagnostics.com. A replay of the webcast will be available following the conclusion of the call and will be archived on the Companys website for 90 days.

About Interpace Biosciences

Interpace Biosciences is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Clinical services, through Interpace Diagnostics, provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX that differentiates lung cancer of primary vs. metastatic origin. In addition, BarreGEN for Barretts Esophagus, is currently in a clinical evaluation program whereby we gather information from physicians using BarreGEN to assist us in positioning the product for full launch, partnering and potentially supporting reimbursement with payers.

Pharma services, through Interpace Pharma Solutions, provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries. Pharma services also advance personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.

For more information, please visit Interpace Biosciences website at http://www.interpace.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are diffiult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Additionally, all forward-looking statements are subject to the Risk Factors detailed from time to time in the Company's most recent Annual Report on Form 10-K filed on April 22, 2020. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contacts:Investor RelationsEdison GroupJoseph Green(646) 653-7030jgreen@edisongroup.com

More here:
Interpace Biosciences to Host Conference Call and Webcast to Discuss First Quarter, 2020 Financial Results on Thursday June 25, 2020 - GlobeNewswire

Sports and Fitness Genomics and Pharmacogenomics Market 2020 : Assurex Health, 23andMe, Future Science Group, Teva Pharmaceutical Industries – 3rd…

Posted on July 1, 2020 by Danzig

Market Research Explore

The Global Sports and Fitness Genomics and Pharmacogenomics Market is thoroughly assessed and explained in an eclectic market study published byMarket Research Explore. The report highlights the current stage and price trends as well as historical statistics of the global Sports and Fitness Genomics and Pharmacogenomics market. The report also underscores vital market facets such as contemporary trends, revenue growth patterns, global demand, and supply in the market. It also analyzes past and current market performance and significant events that help market players and clients to predict future developments in the market.

The report also offers a precise and valuable assessment of global Sports and Fitness Genomics and Pharmacogenomics market share, size, sales volume, revenue, and growth rate. Market value volatility, scope, intact structure, profitability, and overview are also evaluated in the global Sports and Fitness Genomics and Pharmacogenomics market report, which helps clients to make crucial decisions market entry and investment. The report assists Sports and Fitness Genomics and Pharmacogenomics business holders, researchers, product institutes, stakeholders, and company officials in gaining a comprehensive knowledge of the global Sports and Fitness Genomics and Pharmacogenomics market.

Obtain Sample Copy Global Sports and Fitness Genomics and Pharmacogenomics Market Report 2020:https://www.marketresearchexplore.com/report/global-sports-and-fitness-genomics-and-pharmacogenomics-market-report-2019-competitive-landscape-trends-and-opportunities/305488#enquiry

Assessment of leading Sports and Fitness Genomics and Pharmacogenomics market participants:

The report further illuminates changing dynamics, uneven demand-supply ratios, market restraints, limitations, emerging pricing trends, and driving forces that pose positive and negative impacts on market development. In addition, the market rivalry sitch, leading competitors, industry environment, and crucial Sports and Fitness Genomics and Pharmacogenomics market segments are magnified in the report with detailed analysis. Adept analytical models such as SWOT and Porters Five Forces analysis are also employed in the report to provide more profound elucidation of various bargaining powers and threats in the market.

The global Sports and Fitness Genomics and Pharmacogenomics market has been emerging with a healthy CAGR over the last decade and is expected to grow at significant growth rates in the coming years. Akin to other markets, the global Sports and Fitness Genomics and Pharmacogenomics market is exhibiting steady development since current years due to global slowdown, though robust business structures, raw material affluence, technological advancements, and rising demand for the Sports and Fitness Genomics and Pharmacogenomics are likely to boost market revenue in the near future.

Study of major segments of the global Sports and Fitness Genomics and Pharmacogenomics industry:

Coherent survey of Global Sports and Fitness Genomics and Pharmacogenomics Market 2020

Accurate financial evaluation of major Sports and Fitness Genomics and Pharmacogenomics manufacturers are also emphasized in the report that includes assessments of Sports and Fitness Genomics and Pharmacogenomics sales volume, growth rates, CAGR, market share, size, and revenue. The report also sheds light on business stratagems such as recent business expansions through mergers, acquisitions, ventures, and partnerships as well as brand developments and promotional activities. The referred competitive analysis also helps market players in determining the strengths, weaknesses, and market positions of their rivals.

Moreover, each leading participants production techniques, processes, plant locations, raw material sourcing strategies, concentration rates, major vendors, serving segments, equipment, technology adoption, pricing structure, manufacturing cost, Sports and Fitness Genomics and Pharmacogenomics production capacity, import-export, distribution network, and global reach have been examined in the report to offer intact technical and production-related feasibility of competitors.

You can ask for customized information for the Sports and Fitness Genomics and Pharmacogenomics market at[emailprotected].

Read the original post:
Sports and Fitness Genomics and Pharmacogenomics Market 2020 : Assurex Health, 23andMe, Future Science Group, Teva Pharmaceutical Industries - 3rd...

Tech optimization: Unlocking the promise of precision medicine – Healthcare IT News

Posted on May 18, 2020 by Danzig

The healthcare provider organization is a crucial participant in a fast-evolving ecosystem around precision medicine, which includes pharma and biotech companies, medical device manufacturers, national research organizations, academic medical centers, patient advocacy groups, and others.

According to the Precision Medicine Initiative, precision medicine is an approach for disease treatment and prevention that takes into account individual variability in genes, environment and lifestyles.

Precision medicine and personalized medicine often are used interchangeably, but have slightly different connotations with the former focused more on the clinical realm of genomics and the latter taking a more expansive view of social and behavioral health.

Both hold huge potential for better health outcomes but also require complex and challenging technology deployments, changes to clinical workflow, and education for physicians and patients alike.

It is important that the provider CIO help to lead their organization into this new world by considering how existing technologies can be optimized and how new, disruptive technologies can be anticipated over multiple years of capital budget investments, said Dan Kinsella, managing director, healthcare and life science, at consulting giant Deloitte.

Of paramount importance to the typical provider CIO is how to operationalize precision medicine at the point of care. There is not a one-size-fits-all solution for healthcare providers, but there are leading practices to consider whether you are an academic medical center, an integrated delivery network or a community hospital.

In this special report, seven precision medicine technology experts from Accenture, CereCore, Chilmark Research, Deloitte and Orion Health offer healthcare provider organization CIOs and other health IT leaders best practices for optimizing this technology.

Some optimization techniques for precision medicine technologies can take place during system implementation. Implementing precision medicine technology is no different from any other IT implementation project, said Ian McCrae, CEO of Orion Health, a healthcare technology company delivering interoperability, population health and precision medicine systems.

Healthcare CIOs and other health IT leaders must get the basics of change management right by following seven steps, McCrae advised.

Ian McCrae, Orion Health

First, know what problem you are trying to solve, he said. Have this clearly defined from the outset. Dont make the mistake of trying to implement the tech if you havent identified what you will be using it for. Second, ensure the solution makes life easier and delivers a better outcome. If the project fails in either of these areas, then it will fail overall. If the precision medicine tech doesnt make life easier for clinicians, or deliver a better outcome for patients, then why are you implementing it?

Third, have clear roles and responsibilities, including data stewardship, governance and ethics, he suggested. The principles of data governance and stewardship are critical, and must not be overlooked if a project is to be successful, he said.

What are your guidelines for governing the data you will extract? he asked. These guidelines should be clearly aligned with your organizations strategic vision and values. Ethics of data use is another critical area: informed patient consent, the right to withdraw, confidentiality, objectivity the list is long.

Fourth, CIOs need to connect the dots with precision medicine technologies, McCrae advised.

Providing a better prediction without a means to act on it will be a recipe for frustration, he said. Once you have the technology to enable improved predictions, will you also have the resources to apply the learnings? If you cant deliver a better outcome for patients, then its likely your project will fail. Fifth, remember accuracy isnt necessarily the most important thing.

We often compare solutions by how often they get the answer right, without understanding what people want to do with the answer, he added. Knowing that someone is 61.3% likely to get cancer versus 59.8% isnt as important as how quickly you can know it, and what you can do when you find out.

Sixth, stick to the plan and do not get distracted by failures along the way, he said.

We find it hard to continue the development of something when the first stage isnt as successful as we had hoped, he noted. If we are aiming to make precision medicine the gold standard across different fields but the first application isnt successful, that doesnt mean you should throw out the goal.

And seventh, start with specialties where the application is clear, said McCrae. Rather than aiming to implement the tech into a multitude of areas, select one or two specialties where the value of precision medicine is clear. Learn from those before expanding into new areas.

Dr. Charles Bell, chief medical officer at CereCore, a health IT consulting firm, advised that getting the foundational infrastructure established before precision medicine can be applied via the EHR is one best practice for optimizing the use of the technology.

Precision medicine relies on genomics genomics, including pharmacogenomics, has created a vast amount of data, whereas the advent of the EHR has established an enormous data repository, he said. The success of advancing the technology is dependent on the genomic data residing in a repository that the EHR can readily provide access to. Therefore, there is a foundational infrastructure that must be established before precision medicine can be applied leveraging the EHR platforms.

Dr. Charles Bell, CereCore

Genomic medicine is currently informing clinical care. Notable examples are in the treatment of some cancer types, cystic fibrosis and heart disease.

The integration of the EHR, the data repository and the genomics medicine platform becomes essential to translate relevant and crucial data to drive precision medicine care, Bell said. A streamlined workflow must be established that allows clinicians to provide appropriate care from within the EHR using genomics and precision medicine.

Precision medicine requires capturing and analyzing complex data so that it is actionable at the point of care. Evolution of clinician workflow to support precision medicine use cases even those that are relatively simple, such as pharmacogenomics requires multidisciplinary change-management efforts and thoughtful systems integration, said Kinsella of Deloitte.

Furthermore, the challenges of leveraging next-gen sequencing data in clinical decision support exceeds the capability of current EHR systems, except in certain use-cases such as pharmacogenomics, said Kinsellas colleague Connor OBrien, manager at Deloitte Consulting.

Dan Kinsella, Deloitte

This requires external decision support analysis, which often is a manual process, such as the outputs of diagnostic review boards, although we are seeing many attempts at automation being applied, such as the decision-support platforms being deployed by GenomOncology, 2bPrecise, Syapse and others.

When it comes to oncology and other service line roadmaps, health IT leaders should work with their service-line leaders to understand any gaps they have in the technology required to enable excellence in care delivery, Kinsella suggested.

With oncology specifically, ensure that genomic requirements are understood as the capital investments may require multiple fiscal years, he said. Refine your technology roadmap for tumor boards as the future state is likely to include a variety of external contributors such as leading academic medical centers and drug and biotech companies.

Then there are social determinants of health (SDoH). Precision requires understanding of variability in environment and lifestyle in addition to genetics. While most provider organizations are oriented to patients, expansion to the notion of member as an individual who may or may not have a medical record is required, Kinsella insisted.

Value-based contracts with payers define specific cohorts (members) for whom the provider has assumed a level of accountability, he explained. Background and lifestyle questions not typically the focus of most EHR-centric workflows are crucial to the personalization of the care we deliver.

With precision medicine comeinstitutional alliance relationships, said Kinsellas colleague Kate Liebelt, a manager with the Precision Medicine Community of Practice at Deloitte Consulting.

In addition to having the logo on your website, what is the essence of your relationships with your external partners? she asked. Are you sending your data out to a registry without distilling the value of that information for care of your own patients? Increasingly, providers are licensing proprietary data to industry partners. For example, Cancer Commons is a not-for-profit network focused on connecting patients, physicians and providers to access cutting-edge personalized treatments beyond the traditional standard of care, through data sharing.

Entities like the Texas Medical Center Accelerator harness innovation and talent from area healthcare organizations and generate start-up companies with regional, local and international reach, she added.

Real-world evidence is driving innovation in value-based contracting and reimbursement strategies as demonstrated by the CMS Oncology Care Model a new payment and delivery model designed to improve the effectiveness and efficiency of specialty care, she explained. Enablement of precision medicine helps AMCs continue to meet their tripartite mission of education, care delivery and research.

And on a related note, interoperability. Sending and receiving data from across the evolving ecosystem requires that one be at the top of one's game regarding interoperability and, importantly, cybersecurity and compliance from FTTP, to HL7, to FHIR APIand beyond, OBrien said.

Dont leave out your CISO or legal and compliance teams, he said. Current architectures integrate insights from external clinical-decision-support systems, with the EHR serving as the transactional system of record:insights derived from external decision support FHIR API-based integrations that trigger EHR transactions such as pre-populated order sets, modifications to problem lists, and incorporation of CLIA test reports into clinical documentation modules in EHRs.

Jody Ranck, senior analyst at Chilmark Research, a healthcare IT research and consulting firm, advised that integration of genomic data across different EHR systems and across different laboratory and precision medicine platforms is key and challenging for most organizations.

Genetic test results tend to be large files that are difficult to integrate into an EHR, he said. Therefore, having a road map for your precision medicine approach is essential to think ahead several years and analyze which clinical areas will be impacted by the precision medicine program first. Oncology tends to be the most well-developed area, but in our COVID-19 moment, we may see the need for adjustments as significant caseloads of patients are those recovering from treatment with long-term challenges and new knowledge of the virus expands.

Jody Ranck, Chilmark Research

The impact of the pandemic on precision medicine may have some long-term consequences for best practices.

There will be a distributional shift of baseline health characteristics at the population level for the datasets that machine learning algorithms were trained on and new features to these populations that may interact with specific precision medicine initiatives, Ranck said.

The pandemic also has highlighted how poorly prepared the health IT infrastructure was for a public health crisis. Future federal funding, if funded wisely, will have significant funding to enhance precision public health initiatives, particularly those that bring social determinants into the picture. CIOs will face growing pressure to find effective ways to leverage and enhance SDoH efforts through more precise allocation knowledge and financial resources to address the sequelae of the pandemic.

One best practice for optimizing precision medicine technology is to create integration standards that support treatment across ambulatory and inpatient settings, said Bell of CereCore.

The large amount of data that has been generated in both the ambulatory and inpatient settings creates a challenge for integration of the information, he said.

Standards need to be established and refined to aid in the adoption of the technology that will support precision medicine. Clinical-decision-support capabilities must be integrated within the EHR. The evolution of the use of genomics to support precision medicine is dependent on collaborative development by multiple stakeholders.

The list of requirements includes, but is not limited to, genomics specifications, clinical decision support, systems capable of handling genomic information, and resources to bridge the gaps between the data and its use clinically, he added.

An example of the use of pharmacogenetics is that of Warfarin dosing, he said. For a decade now, recommendations for Warfarin dose requirements have been influenced by gene studies. Though there continue to be questions of the effect on specific genotypes in some patient populations, there still has been an improvement in treatment of identified patients with warfarin therapy. The result is that information is gained for a more effective treatment plan and a decreased risk of potentially harmful side effects.

The more specific needs of varied patient populations can be addressed with further use of genetic data that is standardized across the patients settings, he added.

Most EHRs offer a genomics solution to address providers workflow, Bell noted. An order is entered into the system and a pathway provides information to enhance clinical decision-making. It takes into account clinical decision support as well as alternatives if genomic results do not exist or are not accessed within the system. For all vendors, including Meditech, Cerner and Epic, storage and access to genomic repositories needs to be resolved.

eMerge and ClinGen are examples of organizations, along with other resources and efforts, that are developing approaches to integrate genomic information into precise clinical care, he added.

To enable precision medicine, leading provider organizations are refreshing their existing analytics strategies, and hardening core data-management capabilities, said Kinsella of Deloitte. Note that analytics includes descriptive (reports on what happened yesterday), predictive (what might happen in the future) and prescriptive (for example, precision medicine leading practices), he explained.

Regarding reference architecture, use what you have, buy what you need and build what you must, Kinsella said. Explore the capabilities of your core enterprise applications including EHR, ERP and cost accounting, and adjust known levers for example, clinical-decision-support capabilities, lab-management systems, and billing and coding management to operationalize a precision medicine program. Focus on the tools you may require to ensure collection, curation, calculation and consumption of data to generate analytic insights.

On a related front, there are edge technologies and big data. By leveraging open source and edge solutions, providers can augment legacy analytics and data management capacity, Deloittes OBrien said.

For example, providers increasingly are commissioning data lakes to collect and curate data from a variety of internal and external sources, he noted. The velocity of data, including streaming, enables monitoring (for example, sepsis data),disease management and population health surveillance (for example, SDoH), and remote patient-monitoring, tapping into the tsunami of data generated from wearables and IoT.

The need for analysis provenance and traceability of results becomes amplified when dealing with molecular-level data, due to the dynamic nature of scientific discovery, he added.

Genomic variants that are classified as variants of unknown significance today can become clinically significant as scientific knowledge progresses, he said. These requirements will become even more critical as more dynamic types of omics data become clinically significant, such as being realized in the case of metabolomic and proteomic data. Put simply, todays information exhaust may become tomorrows rocket fuel.

In the continuous pursuit of data excellence, CIOs should collaborate with CMIOs, CNIOs and clinical informatics to ensure that key data elements are understood, configured to be captured by the enterprise applications, and, most important, align the workflow so that data is collected predictably, Kinsella said.

Registries, often a standard feature of enterprise EHRs, represent untapped potential, he noted. Typical features include definition of inclusion rules and calculation instructions for specific cohorts of patients. When, for example, does a diabetic patient get tagged as a diabetic patient in the diabetes registry?

Threaded throughout the emerging theme of precision medicine enablement is education around analytics: training in data science, and the application of descriptive, predictive and prescriptive analytics, he added. Increasingly, provider organizations are hiring in-house analytics experts and partnering with entities on their data strategies and capabilities, he said.

Review your organization strategy and align your data sharing approach accordingly, added Deloittes Liebelt. Are you motivated by social good? Academic pursuit of new science? Are you open to earning revenue by sharing de-identified data by building bandwidth to drive robust real-world evidence programs and innovative industry partnerships?

Patient registries and patient-reported outcomes-measurement are a significant means of value creation for provider organizations, particularly in the areas of oncology, rare and orphan disease, and chronic disease management, she said.

Theoretically, providers can predict and validate a patients predisposition to diabetes and track and measure their progress on various treatment regiments through the systematic collection of patient data, for example, population-level data, lab results, patient-reported outcomes, etc., she explained.

As providers continue to make their real-world data available in open, closed or hybrid networks, there is an emergence of innovative partnership opportunities with other provider organizations, pharmaceutical/biotechnology/medical device companies, health insurance companies, and publicly and privately funded research institutions.

On another front, precision medicine is a significant mind-shift for both patients and providers, and the integration of genomic data, or more importantly, knowledge, is a significant challenge, said Ranck of Chilmark Research.

The process of obtaining genetic information is not always as straightforward,and interpreting these results for a patient can be difficult, he said. Most diseases are not a one gene equals X disease type of phenomenon.

Physicians will need more time to digest precision medicine data and render this into actionable information for the patient, he said.

In the context of standard clinical workflows, this is a challenge, he observed. However, there are platforms that can reduce the burden for physicians, but rigorous evaluation of these solutions and the underlying science needs to be done by physicians and scientists with sufficient knowledge of statistics, machine learning and genetics.

Genetic counselors will be essential and may not be in adequate supply as precision medicine matures, he added. Precision medicine is not solely a technological issue and needs to be understood as socio-technical in nature.

Dr. Kaveh Safavi, senior managing director at Accenture Health, offers two best practices when trying to optimize precision medicine technology.

Good clinical practice today needs therapy to be tailored to the genetics of the tumor and the patients immune system for many types of cancer, he explained.

Dr. Kaveh Safavi, Accenture Health

From a CIO perspective, precision medicine achievements mean building a new environment for data acquisition, analysis and decision support in near real time. Oncology decision-support platforms will require managing genetic information of the patient, the patients tumor and other phenotypic data that may not be part of the typical electronic health record.

Since much of oncology care is provided in an ambulatory setting, it also will require seamless data sharing across care settings that may cross boundaries of a clinical enterprise but be essential to treating a patients condition in the most appropriate way possible, Safavi said.

And on another note, there is a growing body of knowledge that combines pharmacology and genomics to develop effective and safe medications and doses tailored to a patients genetic makeup, he said. A delicate part of a CIOs responsibility is selecting and investing in an informatics strategy to support this highly dynamic aspect of clinical care.

An informed drug-prescribing platform requires the ability to gather biological information found in genomes, microbiomes, proteomes, metabolomes, phenotypes and endotypes, he concluded, and applying them to drug-prescribing decision-support platforms used by prescribers should take into account looking for technology architectures with the greatest flexibility to predictably handle large data volumes and data types.

Twitter:@SiwickiHealthITEmail the writer:bill.siwicki@himssmedia.comHealthcare IT News is a HIMSS Media publication.

See the article here:
Tech optimization: Unlocking the promise of precision medicine - Healthcare IT News

Global Genomic Medicine Market to Witness Significant Revenue Growth on Back of Augmenting Demand – Cole of Duty

Posted on June 12, 2020 by Danzig

The National Human Genome Research Institute definesgenomic medicine asan emerging medical discipline that involves using genomic information about an individual as part of their clinical care (e.g., fordiagnostic or therapeutic decision-making) and the health outcomes and policy implications of that clinical use. Genomic medicine is a type of precision medicine in which genomics, epigenomics and other related data is used to accurately aid in individual disease diagnosis. Genomic medicine has novel applications in the fields of oncology, pharmacology, rare and undiagnosed diseases, and infectious disease.Genomic medicine paves way for personalized medicine into clinics and has immense potential to reach the physicians and patients. Genomic medicine has been used for advanced sequencing in cancer pharmacogenomics, rare disorder diagnosis and for tracking of outbreaks of infectious diseases.

Get Free Sample Copy With Impact Analysis Of COVID-19 Of Market Report @https://www.persistencemarketresearch.com/samples/11323

Genomic Medicine Market: Drivers & Restraints

Backed by government investments in precision medicine initiatives such as a multimillion dollar investment by President Obama in January 2015 which aims to improve how to treat and prevent a disease by laying emphasis on its genetic makeup is expected to boost the market growth. Clinical validity and utility of genomic medicine tests is a major issue witnessed in the global market. Also, lack of awareness among healthcare professionals, sluggish adoption of genome medicine, fluctuating regulatory landscape are the factors which could hamper growth of the global genomic medicine market.

Genomic Medicine Market: Segmentation

The global genomic medicine market is classified on the basis of application type, end use and region.

Based on application, the global genomic medicine market is segmented into the following:

Based on end use, the global genomic medicine market is segmented into the following:

Genomic Medicine Market: Overview

Genomic medicine is gaining momentum with expanding applications ranging from risk assessment and diagnosis in healthy individuals to genome-based treatment for patients with complicated disorders. Oncology is a major application of genomics medicine during cancer screening process as diagnostics for genetic and genomic markers. Oncology segment is expected to account for a major share in the global genomic medicine market. Genomic medicine is increasingly being used not only for research purpose but also in clinical applications. In clinical applications, genomic medicine will potentially enhance patient care.

Genomic Medicine Market: Region wise Overview

Geographically, global Genomic Medicine market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan, Middle East and Africa (MEA). Owing to the presence of large number of academic as well as research institutions in the U.S. which are working on genomic medicine to discover next-generation genomic medicines, North America region is projected to lead the global genomic market in terms of value during the forecast period. Also, the presence of several universities offering educational programs coupled with opportunities in scientific research of genomic medicine in the North America and Europe is expected to have positive impact on the regional markets. The genomic medicine concept still in its nascent stage is yet to receive an impetus from the emerging market which are anticipated to hold smaller shares in the global market.

You Can Buy This PMR Healthcare Report From Here @https://www.persistencemarketresearch.com/checkout/11323

Genomic Medicine Market: Key Players

The key research institutes in global genomic medicine market are BioMed Central Ltd., Cleveland Clinic, The University of Texas MD Anderson Cancer Center, The Manchester Centre for Genomic Medicine, Center for Genomic Medicine to name a few. The focus of the top players will be on the identification of effective drug candidates particularly in cancer treatment based on the molecular structure of tumors.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, accessories and applications.

Follow this link:
Global Genomic Medicine Market to Witness Significant Revenue Growth on Back of Augmenting Demand - Cole of Duty

The Global In- vitro diagnostics market is poised to grow at a CAGR of around 5.5% by 2028 – Yahoo Finance UK

Posted on June 18, 2020 by Danzig

Some of the prominent trends that the market is witnessing are growing healthcare expenditure in the emerging markets, huge demand for technologically advanced testing methods, raising incidences of chronic disease and growth opportunities/investment opportunities.

New York, June 17, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global In-Vitro Diagnostics Market Analysis & Trends - Industry Forecast to 2028" - https://www.reportlinker.com/p05246425/?utm_source=GNW

Based on product the market is categorized into data management software, reagents & kits, instruments, software and services and consumables.

By application the market is segmented into cancer, cardiac diseases, infectious disease, drug testing/pharmacogenomics, cardiology, diabetes, nephrology, HIV/AIDS, autoimmune diseases and other applications.

Depending on technology the market is segregated by Molecular Diagnostics (MDX), immunochemistry/immunoassays, clinical chemistry, clinical microbiology, coagulation and haemostasis, haematology and other IVD technologies. Furthermore molecular diagnostics (MDX) is segmented by polymerase chain reaction (PCR), hybridization, isothermal nucleic acid amplification technology (INAAT), microarray, DNA diagnostics and other MDX technologies.

Immunochemistry/Immunoassays are divided into enzyme-linked immunosorbent assay (ELISA), western blot, rapid tests, radioimmunoassay (RIA) and enzyme-linked immunospot (Elispot) assay. Clinical chemistry is categorized into liver panel, renal profile, electrolyte panel, basic metabolic panel, thyroid function panel and specialty chemical tests.

This industry report analyzes the market estimates and forecasts of all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2017, 2018 revenue estimations are presented for 2019 and forecasts till 2028. The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors.

The study presents detailed market analysis with inputs derived from industry professionals across the value chain. A special focus has been made on 23 countries such as U.S., Canada, Mexico, U.K., Germany, Spain, France, Italy, China, Brazil, Saudi Arabia, South Africa, etc. The market data is gathered from extensive primary interviews and secondary research. The market size is calculated based on the revenue generated through sales from all the given segments and sub segments in the research scope. The market sizing analysis includes both top-down and bottom-up approaches for data validation and accuracy measures.

This report provides data tables, includes charts and graphs for visual analysis.

Regional Analysis: North America - US - Canada - Mexico

Europe - France - Germany - Italy - Spain - UK - Rest of Europe

Asia Pacific - China - Japan - India - Australia - New Zealand - Rest of Asia Pacific

Middle East - Saudi Arabia - UAE - Rest of Middle East

Latin America - Argentina - Brazil - Rest of Latin America

Rest of the World - Africa - Caribbean

Report Highlights: - The report provides a detailed analysis on current and future market trends to identify the investment opportunities - Market forecasts till 2028, using estimated market values as the base numbers - Key market trends across the business segments, Regions and Countries - Key developments and strategies observed in the market - Market Dynamics such as Drivers, Restraints, Opportunities and other trends - In-depth company profiles of key players and upcoming prominent players - Growth prospects among the emerging nations through 2028 - Market opportunities and recommendations for new investmentsRead the full report: https://www.reportlinker.com/p05246425/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

See the rest here:
The Global In- vitro diagnostics market is poised to grow at a CAGR of around 5.5% by 2028 - Yahoo Finance UK

Latin America Precision Medicine Market leading to a revenue of USD 6.48 Bn by 2023 – Jewish Life News

Posted on April 30, 2020 by Danzig

Latin America precision medicine market

Precision medicine is a combination of molecular biology techniques and system biology. Big data analytics is expected to drive the market in Latin America. Latin American countries like Brazil, Mexico and Argentina are focusing on providing personalized treatment and therapies to the population, with the use of technologies like next-generation sequencing (NGS), data analytics, etc. Pharmaceuticals and biotech companies are expected to drive the market during the forecast period of 2018-2023, due to the emergence of drug discovery technologies. According to Netscribes, the Latin America precision medicine market is expected to expand at a compound annual growth rate (CAGR) of 9.35% leading to a revenue of USD 6.48 Bn by 2023.

Owing to huge investments in diagnostic research and development in Latin America, there is ample scope for the market to grow during the forecasted period of 2018-2023. Advancements in drug discovery technology, companion diagnostics, next-gene sequencing (NGS), etc will aid market growth in the coming years.The Latin America precision medicine market is classified into three primary segments: based on ecosystem players (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies and healthcare IT specialists/big data companies); based on therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder and infectious diseases); and based on technology (big data analytics, bioinformatics, gene sequencing, pharmacogenomics and companion diagnostics).In the technology segment, drug discovery holds the largest share in the Latin American precision medicine market, whereas big data analytics is expected to grow at the highest CAGR. Cancer comprises of the maximum share in the therapeutics segment due to the higher mortality rate due to cancer.

Download and Get Sample PDF File of this Strategic Report:

https://www.kennethresearch.com/sample-request-10084379

Key growth factors

Advancements in healthcare technology, demand for personalized medical solutions and treatments are the factors driving the precision medicine market in Latin America. The market is also being driven by favorable government laws and regulations for precision medicine. Due to these reasons the precision medicine market is expected to grow at a high CAGR.

Threats and key players

Public healthcare spending in the Latin American countries like Mexico and Brazil is low. So adoption of precision medicine and advanced healthcare support calls for high out-of-pocket spending, which can hinder the growth of the market. Around 31% of the Latin American population cannot access healthcare for economic reasons. Under such circumstances, the development and use of precision medicines can be challenging.Major players in the Latin America precision medicine market are Pfizer, Novartis, Teva Pharmaceuticals Industries etc.

Whats covered in the report?

1. Overview of the Latin America precision medicine market.2. Market drivers and challenges in the Latin America precision medicine market.3. Market trends in the Latin America precision medicine market.4. Historical, current and forecasted market size data for the Latin America precision medicine market segmentation by ecosystem players (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies, healthcare IT specialists/big data companies) by revenue (USD Bn).5. Historical, current and forecasted market size data for the Latin America precision medicine market segmentation by therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder, infectious diseases) by revenue (USD Bn).6. Historical, current and forecasted market size data for the Latin Americaprecision medicine market segmentation by technology (big data analytics, bioinformatics, gene sequencing, pharmacogenomics, companion diagnostics) by revenue (USD Bn).7. Historical, current and forecasted country-wise (Brazil, Mexico and Argentina) market size data (USD Bn) for the Latin America precision medicine market and its segmentations by ecosystem players (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies, healthcare IT specialists/big data companies), by therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder, infectious diseases), and by technology (big data analytics, bioinformatics, gene sequencing, pharmacogenomics, companion diagnostics).8. Analysis of the competitive landscape and profiles of major companies operating in the market.

Why buy?

1. Understand the demand for precision medicine market to determine the viability of the market.2. Determine the developed and emerging markets where precision medicine market is provided.3. Identify the challenge areas and address them.4. Develop strategies based on the drivers, trends and highlights for each of the segments.5. Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed.6. Recognize the key competitors of this market and respond accordingly.7. Knowledge of the initiatives and growth strategies taken up by the major companies and decide on the direction for further growth.8. Define the competitive positioning by comparing the products and services with the key players in the market.

Customizations available

Chapter 1: Executive summary1.1. Market scope and segmentation1.2. Key questions answered1.3. Executive summary

Chapter 2: Latin America precision medicine market overview2.1. Latin America market overview market trends, drivers and challenges2.2. Value chain analysis2.3. Porters Five Forces analysis2.4. Market size- by ecosystem players (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies, healthcare IT specialists/big data companies)2.4. a. Revenue from pharmaceuticals and biotech companies Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations2.4. b. Revenue from clinical laboratories Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations2.4. c. Revenue from diagnostic companies Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations2.4. d. Revenue from healthcare IT specialists/big data companies- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

2.5. Market size- by therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder, infectious diseases)2.5. a. Revenue from cancer Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations2.5. b. Revenue from cardiovascular- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations2.5. c. Revenue from central nervous system Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations2.5. d. Revenue from psychiatric disorder- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations2.5. e. Revenue from infectious diseases- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

2.6. Market size- by technology (big data analytics, bioinformatics, gene sequencing, pharmacogenomics, companion diagnostics)2.6. a. Revenue from big data analytics Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations2.6. b. Revenue from bioinformatics Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations2.6. c. Revenue from gene sequencing Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations2.6. d. Revenue from pharmacogenomics Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations2.6. e. Revenue from companion diagnostics Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

Chapter 3: Latin Americaprecision medicine market- by countries

3.1. Brazil3.1.1. Market overview- market trends, drivers and challenges3.1.2. Market size- by ecosystem players (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies, healthcare IT specialists/big data companies)3.1.2. a. Revenue from pharmaceuticals and biotech companies Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations3.1.2. b. Revenue from clinical laboratories Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations3.1.2. c. Revenue from diagnostic companies Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations3.1.2. d. Revenue from healthcare IT specialists/big data companies Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.1.3. Market size- By therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder, infectious diseases)3.1.3. a. Revenue from cancer Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations3.1.3. b. Revenue from cardiovascular Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations3.1.3. c. Revenue from psychiatric disorder Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations3.1.3. d. Revenue from infectious diseases Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.1.4. Market size- By technology (big data analytics, bioinformatics, gene sequencing, pharmacogenomics, companion diagnostics)3.1.4. a. Revenue from big data analytics Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations3.1.4. b. Revenue from bioinformatics Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations3.1.4. c. Revenue from gene sequencing Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations3.1.4. c. Revenue from pharmacogenomics Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations3.1.4. c. Revenue from companion diagnostics Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.2. Argentina3.2.1. Market overview- market trends, drivers and challenges3.2.2. Market size- by ecosystem players (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies, healthcare IT specialists/big data companies)3.2.2. a. Revenue from pharmaceuticals and biotech companies Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations3.2.2. b. Revenue from clinical laboratories Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations3.2.2. c. Revenue from diagnostic companies Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations3.2.2. d. Revenue from healthcare IT specialists/big data companies Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.2.3. Market size- By therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder, infectious diseases)3.2.3. a. Revenue from cancer Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations3.2.3. b. Revenue from cardiovascular Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations3.2.3. c. Revenue from psychiatric disorder Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations3.2.3. d. Revenue from infectious diseases Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.2.4. Market size- By technology (big data analytics, bioinformatics, gene sequencing, pharmacogenomics, companion diagnostics)3.2.4. a. Revenue from big data analytics Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations3.2.4. b. Revenue from bioinformatics Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations3.2.4. c. Revenue from gene sequencing Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations3.2.4. c. Revenue from pharmacogenomics Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations3.2.4. c. Revenue from companion diagnostics Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.3. Mexico3.3.1. Market overview- market trends, drivers and challenges3.3.2. Market size- by ecosystem players (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies, healthcare IT specialists/big data companies)3.3.2. a. Revenue from pharmaceuticals and biotech companies Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations3.3.2. b. Revenue from clinical laboratories Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations3.3.2. c. Revenue from diagnostic companies Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations3.3.2. d. Revenue from healthcare IT specialists/big data companies Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.3.3. Market size- By therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder, infectious diseases)3.3.3. a. Revenue from cancer Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations3.3.3. b. Revenue from cardiovascular Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations3.3.3. c. Revenue from psychiatric disorder Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations3.3.3. d. Revenue from infectious diseases Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observation

continue

Download and Get Sample PDF File of this Strategic Report:

https://www.kennethresearch.com/sample-request-10084379

About Kenneth Research:

Kenneth ResearchEmail:[emailprotected]Phone: +1 313 462 0609

See the rest here:
Latin America Precision Medicine Market leading to a revenue of USD 6.48 Bn by 2023 - Jewish Life News

Latest Study explores the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Witness Highest Growth in near future -…

Posted on April 30, 2020 by Danzig

Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market size 2020-2025 report, added by Market Study Report, unveils the current & future growth trends of this business sphere in addition to outlining details regarding the myriad geographies that form a part of the regional spectrum of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market. Intricate details about the supply & demand analysis, contributions by the top players, and market share growth statistics of the industry are also elucidated in the report.

Request a sample Report of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market at:https://www.marketstudyreport.com/request-a-sample/2515179?utm_source=algosonline.com&utm_medium=Ram

According to the latest research report, the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market emerges as one of the most proactive business verticals. This research report anticipates this space to garner substantial returns over the forecast period, on account of the broad range of driving forces that is set to transform the market outlook throughout the projected duration. An essence of these driving forces, in conjunction with and excess of additional dynamics related to the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market, such as the threats that are prevalent across this market as well as the growth opportunities, have also been emphasized in the report.

One of the key pointers that makes the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market report worth a buy is the extensive overview it delivers regarding the competitive landscape of the industry. Based on the competitive hierarchy, the study expertly segments the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market into Qiagen NV, Pfizer, F Hoffman La Roche, GE Healthcare, Leica Biosystems Nussloch GmBH, Agilent Technologies, Thermo Fisher Scientific Inc., Foundation Medicine and etc. These companies have been competing with one another in a bid to attain a successful status in the global market.

A brief outline of the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market scope includes:

Ask for Discount on Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Report at:https://www.marketstudyreport.com/check-for-discount/2515179?utm_source=algosonline.com&utm_medium=Ram

The report provides enough data regarding the market share that all of these companies presently account for throughout this vertical, alongside the market share that they are expected to acquire over the estimated period. The study also expounds on particulars related to the product manufactured by each of these companies, that would help industry entrants and key stakeholders develop their competitive analysis and strategy portfolios. Additionally, their decision-making process is set to become more convenient due to the fact that the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market report also highlights an essence of the trends in product pricing and the revenue margins of the major players in the industry.

Important question regarding the regional spectrum of the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market covered by the report:

Some common questions the report answers with regards to the segmentation of the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market

Key takeaways from the study:

For More Details On this Report:https://www.marketstudyreport.com/reports/global-and-china-pharmacogenomics-technology-theranostics-companion-diagnostics-cdx-market-2020-by-company-type-and-application-forecast-to-2025

Some of the Major Highlights of TOC covers:

Executive Summary

Manufacturing Cost Structure Analysis

Development and Manufacturing Plants Analysis of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx)

Key Figures of Major Manufacturers

Related Reports:

2. Global Methadone Hydrochloride Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025Methadone Hydrochloride Market report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Methadone Hydrochloride by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.Read More: https://www.marketstudyreport.com/reports/global-methadone-hydrochloride-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

See the original post here:
Latest Study explores the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Witness Highest Growth in near future -...

Latest Innovation in Therapeutic Drug Monitoring Market and Growing Demand with Important Players, Comprehensive Analysis, Forecast to 2026 with…

Posted on May 1, 2020 by Danzig

Therapeutic drug monitoring is a branch of clinical chemistry and clinical pharmacology which aims at maintaining the drug concentration levels in the body fluids within the particular therapeutic range. The purpose of therapeutic drug monitoring is refining patient care by individually adjusting the drug dosage for better outcomes.TDM is regarded as a module of personalized medicine that interacts with various other disciplines such as pharmacogenomics and pharmacokinetics. Most commonly monitored drugs are digoxin, valproate and carbamazepine.

Get Sample copy of this Report @: https://www.theresearchinsights.com/request_sample.php?id=28418

A new report as a Therapeutic Drug Monitoring market that includes a comprehensive analysis of the market. This includes investigating past progress, ongoing market scenarios, and future prospects. Accurate data on the products, strategies and market share of leading companies in this particular market are mentioned. This report provides a 360-degree overview of the markets competitive landscape. The report further predicts the size and valuation of the market during the forecast period. The report also presents thorough qualitative and quantitative data that affect the expected impact of these factors on the markets future growth prospects.

Companies Profiled in this report includes,

Abbott Laboratories,AgilentTechnologies,Beckman Coulter/Danaher,bioMerieux,Bio-Rad,DiaSorin,EikenChemical,Fujirebio,Grifols,Instrumentation Laboratory/Werfen,Kyowa Medex,Ortho-Clinical Diagnostics,PerkinElmer,Que

After studying key companies, the report focuses on the startups contributing towards the growth of the market. Possible mergers and acquisitions among the startups and key organizations are identified by the reports authors in the study. Most companies in the Therapeutic Drug Monitoring market are currently engaged in adopting new technologies, strategies, product developments, expansions, and long-term contracts to maintain their dominance in the Therapeutic Drug Monitoring market. With the advent of new technologies on a regular basis, players are striving hard to incorporate the latest technology to gain a competitive edge above the rest.

Get up to 20% Discount on this Report @:

https://www.theresearchinsights.com/ask_for_discount.php?id=28418

The report explains a thorough overview of the current growth dynamics of the market with the help of enormous market data covering all key aspects and market segments. The report represents the current state of the market based on a detailed analysis of all key factors that are expected to affect that demand in the near future, it will evaluate the market situation by 2026. And the feasibility of investment. It also provides quantitative and qualitative analysis of every aspect of the market and captures industry trends that emerge.

What the research report offers:

Market definition of the Therapeutic Drug Monitoring market along with the analysis of different influencing factors like drivers, restraints, and opportunities.

Extensive research on the competitive landscape of Therapeutic Drug Monitoring market.

Identification and analysis of micro and macro factors that are and will effect on the growth of the market.

A comprehensive list of key market players operating in the Therapeutic Drug Monitoring market.

Analysis of the different market segments such as type, size, applications, and end-users.

It offers a descriptive analysis of demand-supply chaining in the Therapeutic Drug Monitoring market.

Statistical analysis of some significant economics facts

Figures, charts, graphs, pictures to describe the market clearly.

For More Information:

https://www.theresearchinsights.com/enquiry_before_buying.php?id=28418

Table of Contents:

Therapeutic Drug Monitoring Market Research Report

Chapter 1 Therapeutic Drug Monitoring Market Overview

Chapter 2 Economic Impact on Industry

Chapter 3 Market Competition by Manufacturers

Chapter 4 Production, Revenue (Value) by Region

Chapter 5 Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Production, Revenue (Value), Price Trend by Type

Chapter 7 Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

.CONTINUED FOR TOC

See original here:
Latest Innovation in Therapeutic Drug Monitoring Market and Growing Demand with Important Players, Comprehensive Analysis, Forecast to 2026 with...

Myriad Genetics Announces Publication of a Meta-Analysis Demonstrating the Clinical Utility of the GeneSight Psychotropic Test in People with Major…

Posted on April 20, 2020 by Danzig

SALT LAKE CITY, April 20, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, Myriad or the Company), a global leader in molecular diagnostics and precision medicine, today announced the publication of a meta-analysis of four clinical trials demonstrating that the GeneSight Psychotropic test significantly improves clinical outcomes among patients with major depressive disorder (MDD). The article titled, The Clinical Utility of Combinatorial Pharmacogenetic Testing for Patients with Depression: A Meta-Analysis, appeared online in the journal Pharmacogenomics.

Many commercial insurers and health technology assessors in the United States and internationally consider meta-analyses the highest level of clinical evidence for the treatment of depression, said Bryan Dechairo, Ph.D., executive vice president of Clinical Development at Myriad. Our meta-analysis further demonstrates the consistent clinical utility of the GeneSight Psychotropic test across multiple cohorts of patients with depression. Importantly, the data showed that when clinicians used the GeneSight test to guide clinical care their patients achieved statistically significantly better remission, response and symptom improvement.

The analysis included data from four prospective, controlled trials that evaluated the clinical utility of the GeneSight test in 1,556 people with MDD and who had at least one prior antidepressant medication failure. All four studies evaluated remission, response, and symptom improvement outcomes using the 17-item Hamilton Depression Rating Scale (HAM-D17) among patients whose medication selection was informed by the GeneSight test results (guided care) compared to unguided care (treatment as usual). The results demonstrate that outcomes were significantly improved for patients whose care was guided by the GeneSight test compared to unguided care. Overall remission improved 49 percent (p=.001), response improved by 40 percent and (p<0.01) and symptoms improved 43 percent (p=0.019) relative to treatment as usual.

About GeneSight PsychotropicGeneSight Psychotropic is a pharmacogenomic test that analyzes clinically important variations in DNA. The results of the test can inform doctors about genes that may impact how their patients metabolize or respond to depression medications.

About Myriad GeneticsMyriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra, Prequel, ForeSight, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the GeneSight Psychotropic test significantly improving clinical outcomes among patients with major depressive disorder; the ability of the GeneSight test to guide clinical care for patients; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Assn for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Intl, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Go here to read the rest:
Myriad Genetics Announces Publication of a Meta-Analysis Demonstrating the Clinical Utility of the GeneSight Psychotropic Test in People with Major...

Global Respiratory Infection Diagnostic Markets by Technology, PLEX, Place and Region – COVID-19 Impact & Forecasting/Analysis with Executive…

Posted on April 25, 2020 by Danzig

The "Respiratory Infection Diagnostic Markets by Technology, PLEX, Place and by Region with COVID-19 Impact & Forecasting/Analysis, and Executive and Consultant Guides 2020-2024" report has been added to ResearchAndMarkets.com's offering.

COVID-19 has broken open the market for point of care testing of respiratory infections. Now the competition for market share begins in earnest. Large new markets are opening up. In health facilities, clinics, physicians' offices and elsewhere. And let's not forget the screening market, not just for COVID, but for the rest of the 20 something respiratory pathogens as well. Multiplex vs single plex?

Explore the rapidly changing market as competitors jockey for position in new markets that are not yet well understood.

New technology is forever changing the diagnosis of respiratory infections. Shrinking time to result is opening up markets multiple times the size of current microbiology based practice. Diagnosis has already moved into the Emergency Room. It is now moving to the Physician's Office Lab. Could the Home be next?

The Multiplex factor is creating market confusion while lowering costs and improving care but important factors are holding back progress. The widespread nature of respiratory infections, (young people can get 8 colds a year) means that potential market sizes are enormous. Respiratory, already the largest infectious disease category could multiply in size. This is a growth opportunity for all diagnostic companies. Understand the opportunity and the risk with this in-depth report.

Key Topics Covered

i. Respiratory Infections Diagnostic Market - Strategic Situation Analysis and Impact of COVID-19

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

1.1 What are Respiratory Infections?

1.2 The Role of Diagnosis & Treatment

1.3 Market Definition

1.3.1 Revenue Market Size

1.4 Methodology

1.4.1 Authors

1.4.2 Sources

1.5 A Spending Perspective on Clinical Laboratory Testing

1.5.1 An Historical Look at Clinical Testing

2. Market Overview

2.1 Players in a Dynamic Market

2.1.1 Academic Research Lab

2.1.2 Diagnostic Test Developer

2.1.3 Instrumentation Supplier

2.1.4 Distributor and Reagent Supplier

2.1.5 Independent Testing Lab

2.1.6 Public National/regional lab

2.1.7 Hospital lab

2.1.8 Physician Office Labs

2.1.9 Audit Body

2.1.10 Certification Body

2.2 Respiratory Infections

2.2.1 Upper vs. Lower - Marketing Implications

2.2.2 Understanding the Role of Pneumonia

2.2.3 Bacterial Infections

2.2.3.1 Streptococcal Infections

2.2.3.2 Acute Otitis Media

2.2.3.3 Bacterial Rhinosinusitis

2.2.3.4 Diphtheria

2.2.3.5 Pneumococcal Pneumonia

2.2.3.6 Haemophilus Pneumonia

2.2.3.7 Mycoplasma Pneumonia (Walking Pneumonia)

2.2.3.8 Chlamydial Pneumonias and Psittacosis

2.2.3.9 Health Care-Associated Pneumonia

2.2.3.10 Pseudomonas Pneumonia

2.2.3.11 Pertussis (Whooping Cough)

2.2.3.12 Legionnaires Disease

2.2.4 Tuberculosis - A Special Case

2.2.5 Viral Infections

2.2.5.1 The Common Cold

2.2.5.2 Influenza

2.2.5.3 Viral Pneumonia

2.2.5.4 SARS and MERS

2.2.5.5 Measles (Rubeola)

2.2.5.6 Rubella (German Measles)

2.2.5.7 Chickenpox and Shingles

2.2.6 Fungal and Other Pathogens

2.2.6.1 Histoplasmosis

2.2.6.2 Coccidioidomycosis.

2.2.6.3 Blastomycosis

2.2.6.4 Mucormycosis

2.2.6.5 Aspergillosis

2.2.6.6 Pneumocystis Pneumonia

2.2.6.7 Cryptococcosis

2.3 Diagnostics - A Changing Role

2.3.1 Historical Practice

2.3.2 Current Diagnostics

2.3.3 The Multiplex Vector

2.3.4 Future Diagnostics - The Question of When and Where

2.3.5 Respiratory Infection Diagnostics - The Destination

2.3.6 Diagnostics as Defensive Weapons

3. Market Trends

3.1 Factors Driving Growth

3.1.1. Syndromic Multiplexing

3.1.2 T.A.T

3.1.3 Antimicrobial Resistance Movement

3.1.4 Pandemic Mitigation

3.1.5 An Aging at Risk Population

3.2 Factors Limiting Growth

3.2.1 The Cost Curve

3.2.2 Regulation and coverage

3.2.3 Laissez Faire

3.3 Instrumentation and Automation

3.3.1 The Shrinking Multiplexing Machine

3.3.2 Bioinformatics Networking and Anonymous Reporting

3.4 Diagnostic Technology Development

3.4.1 The Key Role of Time to Result

3.4.2 Single Cell Genomics Changes the Picture

3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment

3.4.4 Pathogen Identification - A Projected Timetable of the Future

Story continues

4. Respiratory Infection Diagnostics Recent Developments

4.1 Recent Developments - Importance and How to Use This Section

4.1.1 Importance of These Developments

4.1.2 How to Use This Section

5. Profiles of Key Players

6. The Global Market for Respiratory Infection Diagnostics

6.1 Global Market Overview by Country

6.1.1 Table - Global Market by Country

6.1.2 Chart - Global Market by Country

See more here:
Global Respiratory Infection Diagnostic Markets by Technology, PLEX, Place and Region - COVID-19 Impact & Forecasting/Analysis with Executive...

Check Your Health: How RX Match can help find the right medication for you – KUTV 2News

Posted on April 25, 2020 by Danzig

KUTV

Rx Match is a test that analyze and interprets each patient;s unique genetic makeup to help doctors determine which medication and dosage might work best with the patient's genes.

"Rx Match is a molecular test that we use to look at a person's DNA to learn how the metabolize certain drugs," said Jason Gillman, Cancer Genomics Director, Intermountain Healthcare.

Variations in a person's DNA can impact how they metabolize and respond to different drugs. RX Match analyzes those variants using pharmacogenomics, a cutting edge field of precision medicine that studies how genes can relate to a patient's response of medication.

The test is a cheek swab, that is then sent to a lab. The results are returned to the doctor about 7 to 14 days later.

The RX Match report includes a response score on antidepressants, opioids, statins, immunosuppressants, antiabetics and many others.

By incorporating genomic information, doctors can pinpoint which medications are most likely to work for their patients. This may help reduce repeat visits for drug side effects.

:There are options there are different ways that we can be more precise in the ways that we prescribe. If a drug is not working or you feel like you might not be on the right drug speak with your physician to see if RX Match is a good match for you," said Gillman.

Joan Eggert has a history of hypertension.

"I've had high blood pressure since age 22. I've been on all kinds of medications up to three or more at once with not really great results," said Joan.

She was placed on a new blood pressure drug shortly before she went on vacation. While she was scuba diving in Fiji, she started to experience shortness of breath.

"Heard the gurgles in my lungs and knew I had Immersion Pulmonary Edema because I am a hyperbaric doctor," said Joan. "Finally we got to shore and after hours on oxygen, I was ok.

Joan was determined to figure out what went wrong. Eventually, she had an RX Match test done.

The test told her she didn't respond well to the medication she was on. Doctors switched her medication and now she is doing better.

"I finally got the answer to my question; the medication I was switched to, I don't metabolize properly," said Joan.

Talk with your doctor if you are interested in learning more about RX Match.

For more information, click here.

Follow Check Your Health on Facebook, Twitter, and YouTube.

View post:
Check Your Health: How RX Match can help find the right medication for you - KUTV 2News

NCLA Warns FDA’s Over-regulation Will Adversely Affect Public Health During Crisis – GlobeNewswire

Posted on April 20, 2020 by Danzig

Washington, D.C., April 14, 2020 (GLOBE NEWSWIRE) -- If weve learned anything from the COVID-19 pandemic, it is that federal agencies that overstep their authority hinder the health and safety of Americans. Other recent regulatory actions by the Food and Drug Administration (FDA) threaten to undermine the ability of clinical laboratories to provide healthcare professionals and patients with information critical to optimizing drug usage and avoiding adverse events. The New Civil Liberties Alliance is especially concerned that the FDAs decision to prevent the dissemination of information related to the impact of genetic variants on drug response (Pharmacogenomics or PGx) will adversely affect public health.

Today NCLA, a nonpartisan, nonprofit civil rights group, filed commentsin support of the Citizen Petition filed on January 9, 2020, by Hyman, Phelps & McNamara, P.C. on behalf of the Coalition to Preserve Access to Pharmacogenomics (Pgx) Information. NCLAs comments focus on two concerns: (1) FDAs efforts to suppress truthful speech violate the First Amendment rights of clinical laboratories as well as of those doctors and patients who wish to receive PGx information from those labs; and (2) FDAs defense of its speech suppression cannot be reconciled with the U.S. Constitutions separation of powers. FDA claims unlimited administrative discretion to prohibit the operation of all clinical laboratories, but it does not have the power to prosecute only those laboratories that disseminate truthful information of which FDA disapproves.

FDAs position also raises significant due-process concerns because it deprives the regulated community of fair notice of how to conform its conduct to FDAs expectations and permits enforcement officials to make up the rules on the fly. Laboratories have long been at the forefront of efforts to quickly develop tests for detecting the presence of new pathogens; they need considerable flexibility to meet the publics time-sensitive need for such tests. FDA should rescind its speech-suppression policy for laboratories that engage in PGx testing. Any new FDA policy on PGx tests should be developed through a notice-and-comment rulemaking proceeding that complies with the Administrative Procedure Act.

NCLA released the following statements:

FDA simply lacks constitutional authority to adopt legislation of its own accord and then proceed to apply that legislation to the regulated community. Only Congress may adopt federal laws restricting individual liberty. FDA should grant the Citizen Petition filed by the Coalition.

Rich Samp, Senior Litigation Counsel, NCLA

Although the FDA claims its speech-suppression policy protects patients, FDAs restrictions on laboratories marketing LDTs are far more likely to cause harm than to benefit public health. Laboratories are in a unique position to disseminate truthful information about gene-drug associations for new drugs. FDAs policy denies patients optimal treatment.

Jared McClain, Staff Counsel, NCLA

ABOUT NCLA

NCLA is a nonpartisan, nonprofit civil rights group founded by prominent legal scholarPhilip Hamburgerto protect constitutional freedoms from violations by the Administrative State. NCLAs public-interest litigation and other pro bono advocacy strive to tame the unlawful power of state and federal agencies and to foster a new civil liberties movement that will help restore Americans fundamental rights.

For more information visit us online atNCLAlegal.org.

###

Read the rest here:
NCLA Warns FDA's Over-regulation Will Adversely Affect Public Health During Crisis - GlobeNewswire

How Coronavirus Pandemic Will Impact Growing Infrastructure Development Projects in Asia-Pacific to Fuel Growth of the Pharmacogenomic (PGx) Testing…

Posted on April 20, 2020 by Danzig

COVID-19 (Coronavirus) has resulted in many advantages and disadvantages for companies in the Pharmacogenomic (PGx) Testing market. Research report of this Pharmacogenomic (PGx) Testing market is highlights key strategies that can help reduce the impact of COVID-19 on diverse business practices.

Analysts of Fact.MR, in a recently published market study, shares important factors that are expected to shape the growth of the Pharmacogenomic (PGx) Testing market over the forecast period (20XX-20XX). The current trends, market drivers, strategic collaborations, and threats are thoroughly evaluated to provide a clear understanding of the current market landscape and the course the Pharmacogenomic (PGx) Testing market is likely to take over the upcoming decade.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=3143

According to the report, the Pharmacogenomic (PGx) Testing market is poised to register a CAGR growth of ~XX% throughout the forecast period owing to several key factors including growing investments in the Pharmacogenomic (PGx) Testing space, innovations with a rise in the number of research and development projects. Fact.MR excels in latest research techniques while curating the market study and gather data from credible and trusted primary and secondary sources.

Important doubts pertaining to the Pharmacogenomic (PGx) Testing market addressed in the report:

The Pharmacogenomic (PGx) Testing market study provides a detailed understanding of the major players operating in the Pharmacogenomic (PGx) Testing market. Some of the leading players discussed

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=3143

Pharmacogenomic (PGx) Testing market segments covered in the report:

Competitive landscape

Comprehensive SWOT analysis of established market players is provided in the report along with critical data including the sales strategy, marketing strategy and pricing strategy adopted by each market player.

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=3143

Key takeaways that add value to our clients business needs?

Visit link:
How Coronavirus Pandemic Will Impact Growing Infrastructure Development Projects in Asia-Pacific to Fuel Growth of the Pharmacogenomic (PGx) Testing...

(2020-2025) Protein Detection and Quantitation Market Estimated To Experience A Hike in Growth | Global Industry Size, Growth, Segments, Revenue,…

Posted on April 14, 2020 by Danzig

Latest Trending Report onProtein Detection and Quantitation Market

The report titled Global Protein Detection and Quantitation Market is one of the most comprehensive and important additions to Alexareports archive of market research studies. It offers detailed research and analysis of key aspects of the global Protein Detection and Quantitation market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Protein Detection and Quantitation market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Protein Detection and Quantitation market is carefully analyzed and researched about by the market analysts.

Protein Detection and Quantitation Market competition by top manufacturers/ Key player Profiled: Thermo Fisher Scientific, Promega, Genecopoeia, Labome, Garland Science

Get PDF Sample Copy of the Report to understand the structure of the complete report:(Including Full TOC, List of Tables & Figures, Chart) : https://www.alexareports.com/report-sample/700682

Global Protein Detection and Quantitation Market is estimated to reach xxx million USD in 2020 and projected to grow at the CAGR of xx% during 2020- 2025. According to the latest report added to the online repository of Alexareports the Protein Detection and Quantitation market has witnessed an unprecedented growth till 2020. The extrapolated future growth is expected to continue at higher rates by 2025.

Based on region, the globalProtein Detection and Quantitation market has been segmented into Americas (North America ((the U.S. and Canada),) and Latin Americas), Europe (Western Europe (Germany, France, Italy, Spain, UK and Rest of Europe) and Eastern Europe), Asia Pacific (Japan, India, China, Australia & South Korea, and Rest of Asia Pacific), and Middle East & Africa (Saudi Arabia, UAE, Kuwait, Qatar, South Africa, and Rest of Middle East & Africa).

Protein Detection and Quantitation Market Segment by Type covers: Bradford, Coomassie, BCA

Protein Detection and Quantitation Market Segment by Industry: Pharmaceuticals and Pharmacogenomics, Diagnostic Research, Agricultural Biotechnology, Breeding and Animal Livestock

After reading the Protein Detection and Quantitation market report, readers get insight into:

*Major drivers and restraining factors, opportunities and challenges, and the competitive landscape*New, promising avenues in key regions*New revenue streams for all players in emerging markets*Focus and changing role of various regulatory agencies in bolstering new opportunities in various regions*Demand and uptake patterns in key industries of the Protein Detection and Quantitation market*New research and development projects in new technologies in key regional markets*Changing revenue share and size of key product segments during the forecast period*Technologies and business models with disruptive potential

Key questions answered in the report:

What will the market growth rate of Protein Detection and Quantitation market?What are the key factors driving the global Protein Detection and Quantitation market size?Who are the key manufacturers in Protein Detection and Quantitation market space?What are the market opportunities, market risk and market overview of the Protein Detection and Quantitationmarket?What are sales, revenue, and price analysis of top manufacturers of Protein Detection and Quantitation market?Who are the distributors, traders, and dealers of Protein Detection and Quantitation market?What are the Protein Detection and Quantitation market opportunities and threats faced by the vendors in the global Protein Detection and Quantitationindustries?What are sales, revenue, and price analysis by types and applications of Protein Detection and Quantitationmarket?What are sales, revenue, and price analysis by regions of Protein Detection and Quantitation industries?

Get a discount on this report now at https://www.alexareports.com/check-discount/700682

Table of ContentsSection 1 Protein Detection and Quantitation Product DefinitionSection 2 Global Protein Detection and Quantitation Market Manufacturer Share and Market Overview2.1 Global Manufacturer Protein Detection and Quantitation Shipments2.2 Global Manufacturer Protein Detection and Quantitation Business Revenue2.3 Global Protein Detection and Quantitation Market OverviewSection 3 Manufacturer Protein Detection and Quantitation Business Introduction3.1 Thermo Fisher Scientific Protein Detection and Quantitation Business Introduction3.1.1 Thermo Fisher Scientific Protein Detection and Quantitation Shipments, Price, Revenue and Gross profit 2014-20193.1.2 Thermo Fisher Scientific Protein Detection and Quantitation Business Distribution by Region3.1.3 Thermo Fisher Scientific Interview Record3.1.4 Thermo Fisher Scientific Protein Detection and Quantitation Business Profile3.1.5 Thermo Fisher Scientific Protein Detection and Quantitation Product Specification3.2 Promega Protein Detection and Quantitation Business Introduction3.2.1 Promega Protein Detection and Quantitation Shipments, Price, Revenue and Gross profit 2014-20193.2.2 Promega Protein Detection and Quantitation Business Distribution by Region3.2.3 Interview Record3.2.4 Promega Protein Detection and Quantitation Business Overview3.2.5 Promega Protein Detection and Quantitation Product Specification3.3 Genecopoeia Protein Detection and Quantitation Business Introduction3.3.1 Genecopoeia Protein Detection and Quantitation Shipments, Price, Revenue and Gross profit 2014-20193.3.2 Genecopoeia Protein Detection and Quantitation Business Distribution by Region3.3.3 Interview Record3.3.4 Genecopoeia Protein Detection and Quantitation Business Overview3.3.5 Genecopoeia Protein Detection and Quantitation Product Specification3.4 Labome Protein Detection and Quantitation Business Introduction3.5 Garland Science Protein Detection and Quantitation Business IntroductionSection 4 Global Protein Detection and Quantitation Market Segmentation (Region Level)4.1 North America Country4.1.1 United States Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.1.2 Canada Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.2 South America Country4.2.1 South America Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.3 Asia Country4.3.1 China Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.3.2 Japan Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.3.3 India Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.3.4 Korea Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.4 Europe Country4.4.1 Germany Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.4.2 UK Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.4.3 France Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.4.4 Italy Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.4.5 Europe Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.5 Other Country and Region4.5.1 Middle East Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.5.2 Africa Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.5.3 GCC Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.6 Global Protein Detection and Quantitation Market Segmentation (Region Level) Analysis 2014-20194.7 Global Protein Detection and Quantitation Market Segmentation (Region Level) AnalysisSection 5 Global Protein Detection and Quantitation Market Segmentation (Product Type Level)5.1 Global Protein Detection and Quantitation Market Segmentation (Product Type Level) Market Size 2014-20195.2 Different Protein Detection and Quantitation Product Type Price 2014-20195.3 Global Protein Detection and Quantitation Market Segmentation (Product Type Level) AnalysisSection 6 Global Protein Detection and Quantitation Market Segmentation (Industry Level)6.1 Global Protein Detection and Quantitation Market Segmentation (Industry Level) Market Size 2014-20196.2 Different Industry Price 2014-20196.3 Global Protein Detection and Quantitation Market Segmentation (Industry Level) AnalysisSection 7 Global Protein Detection and Quantitation Market Segmentation (Channel Level)7.1 Global Protein Detection and Quantitation Market Segmentation (Channel Level) Sales Volume and Share 2014-20197.2 Global Protein Detection and Quantitation Market Segmentation (Channel Level) AnalysisSection 8 Protein Detection and Quantitation Market Forecast 2019-20248.1 Protein Detection and Quantitation Segmentation Market Forecast (Region Level)8.2 Protein Detection and Quantitation Segmentation Market Forecast (Product Type Level)8.3 Protein Detection and Quantitation Segmentation Market Forecast (Industry Level)8.4 Protein Detection and Quantitation Segmentation Market Forecast (Channel Level)Section 9 Protein Detection and Quantitation Segmentation Product Type9.1 Bradford Product Introduction9.2 Coomassie Product Introduction9.3 BCA Product IntroductionSection 10 Protein Detection and Quantitation Segmentation Industry10.1 Pharmaceuticals and Pharmacogenomics Clients10.2 Diagnostic Research Clients10.3 Agricultural Biotechnology Clients10.4 Breeding and Animal Livestock Clients

Do Inquiry About The Report Here: https://www.alexareports.com/send-an-enquiry/700682

About Us:Alexa Reports is a globally celebrated premium market research service provider, with a strong legacy of empowering business with years of experience. We help our clients by implementing decision support system through progressive statistical surveying, in-depth market analysis, and reliable forecast data.

More:
(2020-2025) Protein Detection and Quantitation Market Estimated To Experience A Hike in Growth | Global Industry Size, Growth, Segments, Revenue,...

Select Page ::